Fluence and Northvolt Collaborate to Co-Develop Smart, Sustainable Battery Technology for Grid-Scale Energy Storage
21.4.2021 13:00:00 EEST | Business Wire | Press release
Fluence, a leading global energy storage technology, software and services provider, and Northvolt, the leading European battery developer and manufacturer, today announced an agreement to co-develop next-generation battery technology for grid-scale storage applications. As part of the agreement, Fluence also plans to purchase battery systems from Northvolt.
The companies will draw on Fluence’s systems-level knowledge, including 13 years of energy storage system operating data, and Northvolt’s battery manufacturing expertise and digital competences to develop stationary energy storage products with industry-leading embedded intelligence and total system optimization.
Fluence and Northvolt will work together to develop Northvolt battery hardware and battery management systems optimized for Fluence energy storage solutions. Digital intelligence, tightly integrated through the full product lifecycle from battery manufacturing to end-of-life, will lower total cost of ownership and create unique opportunities to generate value for Fluence customers. The agreement provides Northvolt with an unmatched channel to deliver systems to the global market and expands Fluence’s supply chain to include the leading European-based battery manufacturer.
“Grid-scale energy storage will play a crucial role in transforming the way we power our world, and we are excited to join forces with a true innovator like Northvolt to deliver technology with significant societal and environmental benefits,” said Manuel Perez Dubuc, CEO of Fluence. “This integrated approach to optimize battery technology for Fluence product offerings is intended to make our systems greener, more cost-effective and more impactful, and to help us meet growing demand for sustainable energy storage solutions around the world.”
Battery energy storage is a key element of reliable, resilient, decarbonized electric grids. In response to surging demand for grid-scale battery solutions, Northvolt recently announced a $200M investment to ramp up its stationary energy storage manufacturing capacity.
Both Fluence and Northvolt are committed to decarbonizing the battery supply chain. Northvolt, which has a focus on delivering the lowest carbon footprint possible for its products and developing the world’s greenest battery, will use clean power at its production facilities and is developing advanced recycling capabilities for batteries.
“In order to reach the Paris Agreement, the world needs to make significant investments in building truly sustainable energy grids. And battery systems will play a crucial part in that process. With their technology and reach, Fluence is the perfect partner to help put these solutions in the hands of a large number of customers, and thereby drive the change on the scale that we need,” said Peter Carlsson, CEO and Co-Founder of Northvolt.
Both Fluence and Northvolt will continue to collaborate with OEMs globally to evolve batteries and systems for energy storage applications and will be able to integrate the learnings from the co-development to speed up the transition to a sustainable society.
About Fluence
Fluence, a Siemens and AES company, is helping drive the global energy transition with grid-scale technology, products, and services that help customers maximize the value and performance of single projects or entire portfolios of assets. Fluence delivers energy storage and bidding optimization software products and engineering, delivery, and operational services to customers globally. The company has more than 5.6 GW of storage and optimized bidding assets in operation or contracted in 29 markets.
To learn more about Fluence, please visit: fluenceenergy.com
About Northvolt
Northvolt is a European supplier of sustainable, high-quality battery cells and systems. Founded to enable the European transition to a decarbonized future, the company has made swift progress on its mission to deliver the world’s greenest lithium-ion battery with a minimal CO2 footprint. Among Northvolt industrial partners and customers are ABB, BMW Group, Scania, Siemens, Vattenfall, Vestas and the Volkswagen Group.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005316/en/
Contact information
Media
Fluence: Alison Mickey, alison.mickey@fluenceenergy.com
Northvolt: Jesper Wigardt, jesper.wigardt@northvolt.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom